Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
| Market Cap | 7.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.70M |
| Shares Out | 16.00M |
| EPS (ttm) | -0.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,083 |
| Open | 0.480 |
| Previous Close | 0.470 |
| Day's Range | 0.442 - 0.481 |
| 52-Week Range | 0.417 - 2.870 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2023 |
About SHPH
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treat... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
ROCKVILLE, Md. , Dec. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced submission of an Investigational New Drug (IND) application with...
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023
Webcasted presentation to take place at 10:15am ET ROCKVILLE, Md. , Nov. 30, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pha...
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
ROCKVILLE, Md. , Nov. 14, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes f...
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
ROCKVILLE, Md. , Oct. 31, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference
ROCKVILLE, Md. , Oct. 10, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
Company remains on track to initiate the clinical trial in Q4 of 2023 ROCKVILLE, Md. , Sept. 25, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development...
Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair
ROCKVILLE, Md. , Sept. 13, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outc...
Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform
ROCKVILLE, Md. , Sept. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outco...
Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics
ROCKVILLE, Md. , Aug. 29, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes f...
Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial
ROCKVILLE, Md. , Aug. 3, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcome...
Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update
ROCKVILLE, Md. , May 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes fo...
Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
ROCKVILLE, Md. , May 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes fo...
Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates
ROCKVILLE, Md. , March 22, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outco...
Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update
ROCKVILLE, Md. , March 15, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes ...
Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial
ROCKVILLE, Md. , March 9, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...
Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities
ROCKVILLE, Md. , Feb. 23, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...
Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31
ROCKVILLE, Md. , Jan. 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...
Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023
ROCKVILLE, Md. , Jan. 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...
Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants
ROCKVILLE, Md. , Jan. 12, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...
Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications
ROCKVILLE, Md. , Jan. 10, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...
Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update
ROCKVILLE, Md. , Nov. 15, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...
Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study
ROCKVILLE, Md. , Nov. 3, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcome...
Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors
ROCKVILLE, Md. , Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes...
Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine
Agreement to help advance lead clinical sensitizer drug candidate ROCKVILLE, Md. , Sept. 20, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development sta...